Key result
Ranolazine demonstrates antiarrhythmic benefits in both atrial and ventricular arrhythmias via multichannel blockade.
Why the study?
Does ranolazine exert antiarrhythmic effects in atrial and ventricular arrhythmias?
Does ranolazine exert antiarrhythmic effects in atrial and ventricular arrhythmias?
Answers are grounded in this paper and cite their sources.
Ranolazine, primarily an antianginal agent, demonstrates beneficial antiarrhythmic properties in both atrial and ventricular arrhythmias due to its multichannel-blocking effects.
Ranolazine is an antianginal drug that inhibits a number of ion currents that are important for the genesis of transmembrane cardiac action potential. It was initially developed as an antianginal agent but was found to additionally exert antiarrhythmic actions, due to its multichannel-blocking properties. In recent years, several studies about the antiarrhythmic properties of ranolazine were conducted, demonstrating the beneficial effects of this drug in both atrial and ventricular arrhythmias, such as atrial fibrillation, ventricular premature beats, ventricular tachycardia, torsades de pointes, and ventricular fibrillation. Our aim is to briefly review the main points of these studies, most more experimental than clinical.
No takes yet. Share an insight, caveat, or question.
Vizzardi et al. (2012) conducted a review in Atrial and ventricular arrhythmias. Ranolazine was evaluated. Ranolazine, an antianginal drug with multichannel-blocking properties, demonstrates beneficial antiarrhythmic effects in both atrial and ventricular arrhythmias.
Synapse has enriched 10 related papers. Consider them for comparative context: